Top Tweets for #SAbBio
#SABBio fully-human immunoglobulins (hIgGs) are a breakthrough in immunotherapy. Derived from our patented Tc Bovine, they target complex diseases with multiple dysregulated pathways. See how: https://t.co/CGxyN9Hiee #Immunology #Therapeutics #Biotech
#DiversitAb produces fully-human immunoglobulin #hIgG antibodies in a way that mimics the human immune response. With the potential to target multiple modes of action, discover how #SABBio's platform is leading the way in fully-human antibody therapies: https://t.co/kXIH8HDclT
We're revolutionizing Type 1 Diabetes treatment with SAB-142, a fully-human, multi-target anti-thymocyte immunoglobulin treatment for #T1D. Explore the science behind our breakthrough: https://t.co/zscA1u5F81
#SABBio #Innovation #Therapeutics #Immunology #Biopharma
Our fully-human immunoglobulins (hIgGs) are a breakthrough in immunotherapy. Derived from patented TcBovine hyperimmunization, they target complex diseases with multiple dysregulated pathways. Explore their potent potential: https://t.co/MpvlnO2SKh #SABBio #Immunology #Biotech
Discover SAB-142: a breakthrough fully-human anti-thymocyte globulin treatment for #Type1Diabetes (T1D). Clinically validated and effective in delaying T1D onset. Learn more: https://t.co/6opHsPPzvX
#SABBio #Type1Diabetes #Therapeutics #Immunology #Biopharma #Biotech
Exciting news! Our CEO, Eddie J. Sullivan, Ph.D., presented at @IAmBiotech 2023, discussing our innovative pipeline and promising SAB-176 influenza therapeutic. View the full presentation here: https://t.co/ewE6BQ9ZEP #BIO2023 #Immunotherapy #Influenza #SABBio
Our revolutionary #DiversitAb™ platform transforms disease-fighting. By generating large-scale, high-potency, fully-human immunoglobulins (#hIgGs) across modalities, we are reshaping the field of antibody development. Find out more: https://t.co/O8vtiarml1 #SABBio #Therapeutics
#SABBio transgenic cows carry the entire human IgG heavy and light chain loci, making them the only animal capable of producing fully-human antibodies. Read more: https://t.co/dTcOMddzS3
#Therapeutics #Immunology #Biopharma
#SABBio fully-human immunoglobulins (hIgGs) target multiple epitopes of an antigen, resulting in broad protection against pathogens, mutations & strain changes: https://t.co/ZhJcifD7Lg
Exciting Q1 2023 update from #SABBio! Our immunotherapeutic candidates, SAB-176 and SAB-185, show great promise in treating Type A and Type B influenza and COVID-19. Learn more about our latest #updates, milestones and Q1 2023 financials here: https://t.co/vGlrmnsHsf #biopharma
#SABBio has published promising nonclinical data against pneumonic plague with new asset, SAB-183. The study conducted with @OUSAMRIID demonstrates strong immune protection & response against Yersinia pestis infection: https://t.co/Wjh4Db7NaV #Biosecurity #Immunotherapy
May is #OlderAmericansMonth and we take this opportunity to honor & celebrate the contributions of older Americans. #SABBio is committed to advancing our therapies to provide effective treatment options for diseases affecting the lives of older Americans: https://t.co/ox1aiVxqKa
#SABBio Co-founder, President & CEO, Eddie Sullivan, PhD, delivered an insightful presentation from the Sidoti Virtual Investor Conference about our cutting-edge #immunotherapy platform. Learn more about its potential impact on healthcare: [LINK]: https://t.co/tAyU8vOTBD
![SABBantibody's tweet photo. #SABBio Co-founder, President & CEO, Eddie Sullivan, PhD, delivered an insightful presentation from the Sidoti Virtual Investor Conference about our cutting-edge #immunotherapy platform. Learn more about its potential impact on healthcare: [LINK]: https://t.co/tAyU8vOTBD https://t.co/86tNRiifj1](https://pbs.twimg.com/media/Fv3h7soWABEyjyf.jpg)
#DiversitAb is a game-changer for the field of #antibody production. We're working to advance this technology to produce potent #humanIgG across multiple modalities. Learn more: https://t.co/zMk5ypysol #SAbBio
#SABBio's SAB-142 has shown promising results in pre-clinical trials, offering a safer, fully-human immunoglobulin (hIgG) alternative to currently available #therapeutics for Type 1 #Diabetes. Learn more about how we're innovating to improve lives! https://t.co/Wy53W0qPgQ
Our #DiversitAb™ platform revolutionizes the way we fight disease. Its ability to produce large scale fully-human immunoglobulins #hIgGs across multiple modalities is changing the game in antibody development. Learn more:https://t.co/LBuH4hQ0yQ #SABBio #AntibodyDevelopment"
Our first fully-human anti-thymocyte hpAB therapeutic, #SAB142, can be administered multiple times without causing immune-related adverse reactions. It has potential to impact millions with #Type1Diabetes. Learn more: https://t.co/eFy0dzp9Gs #SABBio #T1D #Immunotherapy
Last Seen Hashtags on Sotwe
silkware
Seen from United States
4into1
Seen from United States
辱骂
Seen from Germany
BeybladeTeam
Seen from United States
optimalCordclamping
Seen from United States
kamenridermyth
Seen from Australia
tambiensoychido
Seen from United States
findom
Seen from United States
wifedp
Seen from United States
GustavoBolivarMalaPaga
Seen from United States
Most Popular Users
Elon Musk 
@elonmusk
241.5M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
113.9M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.6M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.7M followers
KATY PERRY
@katyperry
89.7M followers
Taylor Swift
@taylorswift13
83.6M followers
Lady Gaga
@ladygaga
75.1M followers
Virat Kohli
@imvkohli
72.9M followers
Kim Kardashian
@kimkardashian
70.7M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
65.9M followers
Bill Gates
@billgates
64.9M followers
Selena Gomez
@selenagomez
62.8M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers